<DOC>
	<DOCNO>NCT00584805</DOCNO>
	<brief_summary>This study design determine safety immunogenicity Eastern Equine Encephalitis ( EEE ) Vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Eastern Equine Encephalitis ( EEE ) Vaccine</brief_title>
	<detailed_description>The primary objective assess safety Eastern Equine Encephalitis Vaccine , Inactivated , Dried EEE , TSI GSD 104 , assess immunogenicity Eastern Equine Encephalitis Vaccine , Inactivated , Dried EEE , TSI GSD 104 .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalomyelitis , Equine</mesh_term>
	<mesh_term>Encephalomyelitis , Eastern Equine</mesh_term>
	<criteria>At least 18 year old . EEE PRNT80 ≤ 1:20 . EEE PRNT80 ≤ 1:40 booster series ( female ) Negative pregnancy test day vaccination . Not plan pregnancy 3 month . At risk exposure virulent EEE virus ( uptodate risk assessment ) . Uptodate ( within 1 year ) physical examination/tests . Sign date approve informed consent . Willing return followup visit . Agree report adverse event ( AE ) 28 day vaccination . Over 65 year age ( Primary Immunization ) . Clinically significant abnormal lab result include evidence Hepatitis C , Hepatitis B carrier state , elevate ( 2X normal ) liver function test . History immunodeficiency current treatment immunosuppressive medication . ( female ) Currently breastfeed . Confirmed human immunodeficiency virus ( HIV ) titer . Any known allergy component vaccine . A medical condition , judgment Principal Investigator ( PI ) , would impact subject safety ( i.e.vaccination exposure another Alphavirus ) . Administration IND product live vaccine within 28 day EEE . Any unresolved AEs result previous immunization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>EEE</keyword>
</DOC>